Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the AMPLIFY Phase III trial of Calquence plus venetoclax as a first line treatment for chronic lymphocytic leukemia

Ticker(s): AZN, ABBV, RHHBY

Who's the expert?

Institution: AHN Cancer Institute

Hematologist with the AHN Cancer Institute.
Currently manages 35 patients for CLL
Specializes in treating disorders and cancers of the blood, such as lymphoma, leukemia, myeloma and is involved in hematology research.

Interview Goal

This call will feature a discussion on the current treatment landscape and the potential of Calquence (acalabrutinib) in combination with venetoclax as a treatment for CLL.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.